This Dividend King Has Raised Its Payout for More Than 60 Straight Years. But Is the Stock Still a Buy?

Johnson & Johnson raised its quarterly dividend 3.1% to $1.34/share (=$5.36 annual), its 64th consecutive annual increase; the dividend is covered at ~46% of expected 2026 non-GAAP earnings and yields ~2.1% at ~$257. Operationally, total Q1 2026 revenue rose 9.9% to $24.1B as Darzalex (+~22% to nearly $4B) and Tremfya (+~68% to ~$1.6B) offset Stelara’s ~60% YoY decline to $656M. Management guided adjusted EPS to about $11.55 for the year, but the stock’s >60% run over the past year leaves valuation elevated (~22x earnings), shifting the debate from dividend safety to whether the premium is justified amid ongoing talc litigation.

Analysis

The setup is no longer about whether JNJ deserves a safety premium; it is about whether that premium can keep expanding when the stock already prices in much of the good news. At ~22x earnings, the hurdle is now earnings revision intensity, not dividend credibility. That matters because names like JNJ tend to underperform once the market stops rewarding balance-sheet quality and starts demanding visible acceleration; the cash return is secure, but secure yield alone is not enough to justify fresh multiple expansion when 10Y yields remain restrictive.

Second-order, the real winners are the companies taking share in the same therapeutic baskets and the cheaper large-cap pharma names that still have room for rerating. If JNJ continues to trade like a “compounder bond proxy,” capital is more likely to rotate toward ABBV, MRK, and selected healthcare ETFs with lower starting valuations and clearer EPS leverage. The flip side is that any deceleration in Darzalex/Tremfya or acquisition integration issues would hit the stock disproportionately because the market has already paid for the post-Stelara transition.

The main risk/catalyst is not litigation bankruptcy-style damage; it is headline drag plus a guidance miss that forces the market to revisit the premium multiple. Over the next 1-3 months, the key check is whether management can keep raising the forward EPS path as biosimilar pressure deepens. Over 6-18 months, the thesis is falsified if the company cannot replace maturing franchises with enough organic growth to justify a premium to the S&P. Contrarian view: consensus may be underestimating how little upside is left once the “quality discount” disappears; the stock can remain excellent and still be a poor new-money return from here.

Key Decisions for Investors

• Do not initiate new long JNJ at current levels; wait for a 5%-8% pullback or a forward P/E closer to 19x-20x before buying. At present, upside looks single-digit while downside on any guide-down is easily mid-teens.
• Pair trade: long ABBV / short JNJ over 3-6 months. Both are defensive pharma exposures, but JNJ has less valuation cushion and more litigation noise; ABBV has more earnings leverage if sentiment shifts toward cheaper growth. Stop if JNJ outperforms by >5% or if JNJ guides materially above current expectations.
• For existing JNJ holders, sell 3-6 month covered calls ~5% out of the money to monetize the premium while capping the low-conviction upside. The stock is more likely to grind than trend without a new catalyst.
• Set an alert on the next earnings/guidance update: if consensus EPS revisions fail to rise by at least low-single digits over the next two quarters, treat the current premium as vulnerable to multiple compression back toward the sector.
• Use JNJ weakness as a funding source for higher-beta healthcare exposure rather than adding outright; a basket like MRK/ABBV versus JNJ offers better risk/reward if the market rotates toward value within pharma.